Purpose: Serum CA-125
has been shown to be a sensitive tumor marker of recurrent ovarian
cancer. The goal of this study was to evaluate the use of
2-[F-18]fluoro-2-deoxy-d-glucose-positron emission tomography/computed
tomography (FDG-PET/CT) in the early detection of recurrent ovarian
cancer in patients with low-level increases in serum CA-125 levels.